drugset / Trial / NCT01262794
Pharmacokinetic (PK)/Pharmacodynamic (PD), Study of Single-dose Subcutaneous CDP6038 in Healthy Japanese Male Subjects
RandomizedParallel-groupDouble-blind
Summary
To evaluate the safety and tolerability of CDP6038 following single dose subcutaneous (sc) administration of CDP6038 to Japanese subjects. To evaluate the Pharmacokinetics of CDP6038 following single dose sc administration of CDP6038 to Japanese subjects
Timeline
- Start
- 2010-11
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olokizumab | Monoclonal antibody | 0.3 mg/kg | Subcutaneous |
| Subject | Olokizumab | Monoclonal antibody | 1 mg/kg | Subcutaneous |
| Subject | Olokizumab | Monoclonal antibody | 3 mg/kg | Subcutaneous |
| Subject | Olokizumab | Monoclonal antibody | 6 mg/kg | Subcutaneous |
Indications
No indication recorded.